SS-31 50mg

Research

Initial Comments on the Peptide/Overview

SS-31 is a synthetic low-molecular-weight peptide belonging to the class of mitochondria-targeted peptides. Its sequence (D-Arg-dimethylTyr-Lys-Phe-NH₂) was designed to readily penetrate cell membranes and selectively accumulate in the inner mitochondrial membrane, independent of membrane potential.

Unlike classical antioxidants, SS-31 does not act solely as a scavenger of reactive species, but rather as a functional modulator of mitochondrial bioenergetics. Its primary molecular target is cardiolipin, a phospholipid essential for the structural organization of the electron transport chain.

The peptide has been widely investigated in experimental models related to mitochondrial dysfunction, aging, cardiovascular diseases, and metabolic disorders.

Mechanism of Action and Inhibition

SS-31 exhibits a mechanism of action centered on stabilizing mitochondrial function.

1. Interaction with cardiolipin

• Selective binding to cardiolipin in the inner mitochondrial membrane
• Preservation of the organization of electron transport chain complexes
• Prevention of cardiolipin lipid peroxidation

2. Modulation of the respiratory chain

• Improved efficiency of electron transport
• Reduction of electron leak
• Decreased formation of reactive oxygen species (ROS)

3. Protection against mitochondrial dysfunction

• Maintenance of mitochondrial membrane potential
• Reduction of mitochondrial permeability transition pore (mPTP) opening
• Preservation of ATP production

4. Indirect effects

• Reduction of intracellular oxidative stress
• Modulation of apoptotic pathways

SS-31 does not function as a classical enzyme inhibitor but rather exerts modulatory and stabilizing effects on mitochondrial structures and processes.

Metabolic Impacts Investigated

Numerous preclinical and clinical studies have evaluated the metabolic effects of SS-31:

1. Cellular bioenergetics

• Increased mitochondrial efficiency
• Improved ATP production
• Reduction of cellular energetic dysfunction

2. Oxidative metabolism

• Reduction of mitochondrial ROS
• Decreased oxidative damage to proteins, lipids, and DNA

3. Muscle metabolism

• Improved muscle function in aging models
• Increased fatigue resistance
• Preservation of mitochondrial integrity in skeletal muscle

4. Cardiovascular metabolism

• Improved cardiac function in heart failure models
• Reduction of cardiac remodeling
• Protection against ischemia-reperfusion injury

5. Systemic metabolism

• Potential improvement in insulin sensitivity (in some models)
• Reduction of inflammation associated with oxidative stress

Investigation in Oncological Models

The role of SS-31 in oncological models remains limited and is not its primary focus of investigation.

However, some experimental considerations include:

• Modulation of mitochondrial function may influence cell survival
• Reduction of ROS may impact signaling pathways associated with proliferation
• In certain contexts, mitochondrial protection could theoretically support cell survival (including tumor cells)

On the other hand:

• There is no consistent evidence of direct pro-tumoral effects
• Oncology-specific studies remain scarce and inconclusive

Thus, the role of SS-31 in cancer remains poorly defined and requires further investigation.

Specific Action of the Peptide SS-31

Cardiolipin-targeted mitochondrial protection

The primary specific action of SS-31 is the stabilization of cardiolipin in the inner mitochondrial membrane.

This results in:

• Preservation of respiratory supercomplex structure
• Reduction of lipid peroxidation
• Maintenance of mitochondrial functional integrity

This characteristic differentiates SS-31 from conventional antioxidants, as its action is localized and structurally targeted rather than purely chemical.

Pharmacokinetic Considerations in Research

SS-31 exhibits pharmacokinetic properties consistent with small cationic peptides:

• Rapid cellular penetration
• Preferential distribution to mitochondria
• Ability to cross membranes independently of specific transporters

Additional aspects:

• Relatively short circulating half-life, but with intracellular functional retention
• Parenteral administration in studies (primarily intravenous or subcutaneous)
• Reduced initial degradation due to the presence of D-amino acids

Detailed human pharmacokinetics remain under investigation in clinical studies.

Other Relevant Research Associations

• Aging and mitochondrial dysfunction
• Neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s)
• Ischemia-reperfusion injury
• Metabolic diseases associated with mitochondrial dysfunction
• Nephropathies and acute kidney injury
• Muscle fatigue and sarcopenia

SS-31 is frequently studied as a mitochondria-protective agent in various conditions characterized by oxidative stress and impaired bioenergetics.

Final Considerations

SS-31 is a mitochondria-targeted peptide with a mechanism centered on cardiolipin interaction and stabilization of cellular bioenergetics. Its effects extend beyond simple antioxidant activity, involving structural and functional preservation of the respiratory chain.

Available data suggest benefits in models of mitochondrial dysfunction, including improvements in energy metabolism, muscle function, and cardiovascular health. However, its clinical application still depends on further validation in controlled studies.

Its current use remains predominantly restricted to experimental and research contexts, particularly in areas related to bioenergetics and mitochondrial medicine.

References

Szeto, H. H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029–2050. https://doi.org/10.1111/bph.12461

Zhao, K., Luo, G., Giannelli, S., Szeto, H. H. (2005). Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis. Biochemical Pharmacology, 70(12), 1796–1806. https://doi.org/10.1016/j.bcp.2005.09.017

Dai, D. F., Chen, T., Szeto, H., Nieves-Cintrón, M., Kutyavin, V., Santana, L. F., Rabinovitch, P. S. (2011). Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. Journal of the American College of Cardiology, 58(1), 73–82. https://doi.org/10.1016/j.jacc.2010.12.044

Siegel, M. P., Kruse, S. E., Percival, J. M., Goh, J., White, C. C., Hopkins, H. C., Kavanagh, T. J., Szeto, H. H., Rabinovitch, P. S., Marcinek, D. J. (2013). Mitochondrial-targeted peptide improves mitochondrial bioenergetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763–771. https://doi.org/10.1111/acel.12108

Elamipretide Clinical Development Overview (various ongoing clinical studies on SS-31).